Stockreport

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Allakos Inc.  (ALLK) 
Last allakos inc. earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF – Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with [Read more]